Apellis and Sobi have amended their partnership agreement for paroxysmal nocturnal hemoglobinuria (PNH) treatment Empaveli, ...

Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. See ...

BridgeBio has received a $300 million upfront payment, strengthening the Company’s balance sheet, and supporting the launch ...

Passive investing in index funds can generate returns that roughly match the overall market. But you can significantly boost your returns by picking above-average stocks. For example, the Royalty ...

Turnstone Biologics has limped to the exit. Xoma Royalty is buying Turnstone for less than $8 million, marking a low-profile ...

Royalty Pharma’s first quarter reflected a stable performance, with revenue in line with Wall Street expectations and ...

Following a thorough review process conducted with the assistance of its legal and financial advisors, the Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

The funding will support the development of Revolution's RAS(ON) inhibitor daraxonrasib in exchange for tiered royalties on its sales.

Royalty Pharma will pay up to $2 billion to Revolution Medicines to support the development and sales of an experimental drug ...

Revolution Medicines projected its cash and equivalents of $2.1 billion would last into the second half of 2027. With new ...

A total of $1.25 billion of the money pledged by Royalty has been agreed in exchange for tiered royalties on net sales of ...